Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
05 Fevereiro 2024 - 10:30AM
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics”
or “Elicio”), a clinical-stage biotechnology company developing a
pipeline of novel immunotherapies for the treatment of cancer,
today announced that Robert Connelly, Chief Executive Officer,
will present at the upcoming Oppenheimer 34th Annual Healthcare
Life Sciences Conference on February 13, 2024 at 12:40 PM ET.
A live webcast of the presentation will be accessible under
“Events” in the Investors section of Elicio’s website and will be
available on-demand for 90 days following the event.
About Elicio TherapeuticsElicio Therapeutics is
a clinical-stage biotechnology company developing a pipeline of
novel immunotherapies for the treatment of cancer. By combining
expertise in immunology and immunotherapy, Elicio is engineering
investigational Amphiphile (“AMP”) immunotherapies intended to
precisely target and fully engage the lymph nodes, the site in our
bodies where the immune response is orchestrated. Elicio is
engineering lymph node-targeted AMPlifiers, immunomodulators,
adjuvants and vaccines for an array of aggressive cancers.
Media ContactKristin PolitiLifeSci
Communicationskpoliti@lifescicomms.com646-876-4783
Investor Relations ContactHeather
DiVecchiaElicio TherapeuticsIR@elicio.com857-209-0153
Elicio Therapeutics (NASDAQ:ELTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Elicio Therapeutics (NASDAQ:ELTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024